Korean J Gastroenterol.  2021 Apr;77(4):160-163. 10.4166/kjg.2021.403.

How to Cope with COVID-19 in Patients with Inflammatory Bowel Disease

• Lee YJ

• KMID: 2515136
• DOI: http://doi.org/10.4166/kjg.2021.403

Abstract

Patients with inflammatory bowel disease (IBD) are generally considered to be more vulnerable to coronavirus disease 2019 (COVID-19). In addition, there are many concerns about the risk of severe COVID-19 infection in patients with IBD. Because the uncertainty of COVID-19 can cause confusions for patients with chronic diseases, physicians should be able to provide adequate advice for optimal treatment for patients with IBD. As the COVID-19 pandemic continues, current knowledge of COVID-19 is changing based on numerous empirical guidance and clinical data being updated daily. Based on the latest evidence, we will discuss the appropriate strategy and management of patients with IBD in the era of COVID-19.

Keyword

COVID-19; Pandemics; Inflammatory bowel diseases

Reference

1. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. 2020; Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 158:1831–1833.e3. DOI: 10.1053/j.gastro.2020.02.055. PMID: 32142773. PMCID: PMC7130181.

2. Cheung KS, Hung IFN, Chan PPY, et al. 2020; Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 159:81–95. DOI: 10.1053/j.gastro.2020.03.065. PMID: 32251668. PMCID: PMC7194936.

3. Pan L, Mu M, Yang P, et al. 2020; Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 115:766–773. DOI: 10.14309/ajg.0000000000000620. PMID: 32287140. PMCID: PMC7172492.

4. Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. 2020; Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology. 159:1575–1578.e4. DOI: 10.1053/j.gastro.2020.06.003. PMID: 32522507. PMCID: PMC7702184.

5. Jin X, Lian JS, Hu JH, et al. 2020; Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 69:1002–1009. DOI: 10.1136/gutjnl-2020-320926. PMID: 32213556. PMCID: PMC7133387.

6. Wu Y, Guo C, Tang L, et al. 2020; Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 5:434–435. DOI: 10.1016/S2468-1253(20)30083-2.

7. Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. 2020; The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 26:e132–e133. DOI: 10.1093/ibd/izaa170. PMID: 32619003. PMCID: PMC7337801.

8. Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. 2020; Oct. 19. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? Results from a nationwide veterans' affairs cohort study. Am J Gastroenterol. [Epub ahead of print]. DOI: 10.14309/ajg.0000000000001012. PMID: 33079751.

9. Bezzio C, Saibeni S, Variola A, et al. 2020; Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 69:1213–1217. DOI: 10.1136/gutjnl-2020-321411. PMID: 32354990. PMCID: PMC7242872.

10. Ungaro RC, Brenner EJ, Gearry RB, et al. 2021; Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 70:725–732. DOI: 10.1136/gutjnl-2020-322539. PMID: 33082265.

11. Siegel CA, Christensen B, Kornbluth A, et al. 2020; Guidance for restarting inflammatory bowel disease therapy in patients who withheld immunosuppressant medications during COVID-19. J Crohns Colitis. 14:S769–S773. DOI: 10.1093/ecco-jcc/jjaa135. PMID: 33085972. PMCID: PMC7665410.

12. Brenner EJ, Ungaro RC, Gearry RB, et al. 2020; Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 159:481–491.e3. DOI: 10.1053/j.gastro.2020.05.032. PMID: 32425234. PMCID: PMC7233252.

13. Agrawal M, Brenner EJ, Zhang X, et al. 2021; Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry. Inflamm Bowel Dis. 27:585–589. DOI: 10.1093/ibd/izaa303. PMID: 33325523. PMCID: PMC7799122.

14. Magro F, Rahier JF, Abreu C, et al. 2020; Inflammatory bowel disease management during the COVID-19 outbreak: the ten dós and don'ts from the ECCO-COVID taskforce. J Crohns Colitis. 14:S798–S806. DOI: 10.1093/ecco-jcc/jjaa160. PMID: 32722754. PMCID: PMC7454472.

15. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. 2020; AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 159:350–357. DOI: 10.1053/j.gastro.2020.04.012. PMID: 32283100. PMCID: PMC7151253.

16. Lee JY, Hong SW, Hyun M, et al. 2020; Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. Int J Infect Dis. 98:462–466. DOI: 10.1016/j.ijid.2020.07.017. PMID: 32702415. PMCID: PMC7371586.

17. Chung HS, Lee DE, Kim JK, et al. 2020; Revised triage and surveillance protocols for temporary emergency department closures in tertiary hospitals as a response to COVID-19 crisis in Daegu metropolitan city. J Korean Med Sci. 35:e189. DOI: 10.3346/jkms.2020.35.e189. PMID: 32419401. PMCID: PMC7234857.

18. Fiorino G, Allocca M, Furfaro F, et al. 2020; Inflammatory bowel disease care in the COVID-19 pandemic era: the humanitas, milan, experience. J Crohns Colitis. 14:1330–1333. DOI: 10.1093/ecco-jcc/jjaa058. PMID: 32211765. PMCID: PMC7184487.